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Abstract
Interleukin (IL)-18 is a cytokine isolated as an important modulator of immune responses and subsequently shown
to be pleiotropic. IL-18 and its receptors are expressed in the central nervous system (CNS) where they participate
in neuroinflammatory/neurodegenerative processes but also influence homeostasis and behavior. Work on IL-18
null mice, the localization of the IL-18 receptor complex in neurons and the neuronal expression of decoy isoforms
of the receptor subunits are beginning to reveal the complexity and the significance of the IL-18 system in the
CNS. This review summarizes current knowledge on the central role of IL-18 in health and disease.
Introduction
Interleukin (IL)-18 was isolated in 1995 as a co-factor
that, in synergism with IL-12, stimulated the production
of gamma interferon (INF-g) in Th1 cells [1]. Since then
extensive in vitro and in vivo studies have identified IL-
18 as an important link between innate and adaptive
immune responses and a regulator of both cellular and
humoral immunity [2-4]. Constitutively produced as an
inactive precursor by several cell types IL-18 is secreted
in its active form following maturation by caspase 1 in
response to inflammatory and infectious stimuli. In
addition to its effects on Th1 cells, IL-18 is a strong sti-
mulator of the activity of natural killer cells alone or in
combination with IL-15, and of CD8
+ lymphocytes.
Together with IL-2, IL-18 can also stimulate the pro-
duction of IL-13 and of other Th2 cytokines. Thus, it is
perhaps not surprising that IL-18 was found to be asso-
ciated with or demonstrated to contribute to numerous
inflammatory-associated disorders. These include infec-
tions, autoimmune diseases, rheumatoid arthritis, can-
cer, as well as metabolic syndrome and atherosclerosis
[5-11].
IL-18 had not originally been expected to cross an
intact blood brain barrier and its immunological effector
cells are not normally found in the healthy brain. Yet,
studies on the possible role of IL-18 in the central ner-
vous system (CNS), initiated soon after its cloning, were
prompted primarily by its similarities with IL-1, which
was already demonstrated to have central action. It was
soon found that IL-18 could be synthesized centrally
and its receptor subunits were now demonstrated to be
broadly expressed in neurons. When recombinant inter-
leukin 18 became available it also became clear that IL-
18 was active centrally. Work on mice null for IL-18 or
its receptor subunit alpha is helping to decipher the
action of this cytokine in the brain. Finally, the recent
discovery of novel IL-18 receptor subunits in the brain
has revealed the complexity of the IL-18 system and
may lead to better understanding of both the similarities
and opposing actions of IL-1 and IL-18. This review
summarizes more than a decade of work aimed at
understanding how the IL-18 system contributes to local
central inflammatory processes or can influence neuro-
nal function and behavior. A summary of the literature
supporting the involvement of IL-18 in neurophysiologi-
cal and neuropathological conditions is presented in
Table 1.
Components of the IL-18 system
IL-18 is synthesized as an inactive 24-kDa precursor
protein that is subsequently processed by caspase-1 into
i t sm a t u r es e c r e t a b l ef o r m ,w h i c hh a sam o l e c u l a r
weight of 18 kDa [4,12-16]. Pro-IL-18 can also be pro-
cessed into its active form by various extracellular
enzymes including protease 3 (PR-3), serine protease,
elastase and cathepsin G [17-19]. Only the mature pep-
tide is reported to be biologically active.
The existence of a putative short isoform of IL-18
resulting from alternative splicing removing 57 bp/19 aa
was first described in rat adrenal glands (IL-18a)[ 2 0 ]
and subsequently in mouse spleens (IL-18s) [21]. Recom-
binant IL-18s did not display IL-18-like activity in stimu-
lating INF-g production when tested alone but appeared
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date this isoform has not been reported in the CNS.
The IL-18 receptor (IL-18R) belongs to the interleukin
1 receptor/Toll like receptor superfamily. It is comprised
of two subunits, IL-18Ra (also known as IL-1Rrp1, IL-
18R1 or IL-1R5) and IL-18Rb (also termed IL-18RacP,
IL-18RII or IL-1R7) both with three extracellular
immunoglobuling-like domains and one intracellular
Toll/IL-1 receptor (TIR) domain [22,23]. IL-18 is
believed to bind directly only to IL-18Ra with signal
transduction occurring after recruitment of IL-18Rb to
form a high-affinity heterotrimeric complex with IL-
18Ra/IL-18 [23-25].
Isoforms of both IL-18Ra and IL-18Rb were recently
described in vivo in the CNS. They include a short tran-
script for IL-18Ra encoding for a receptor subunit lack-
ing the TIR domain arbitrarily named IL-18Ra type II
[26]. Since the TIR domain is required for signaling, IL-
18Ra type II was proposed to be a decoy receptor, simi-
lar to the type II IL-1R [27]. In addition, a truncated
form of IL-18Rb comprising only one of the three
immunoglobulin domains was described in rat and
human tissues including the brain [28,29]. This form
was proposed to act as a soluble negative regulator of
IL-18 action by stabilizing IL-18 binding to IL-18Ra yet
preventing signaling.
Another negative regulator of IL-18 action is the IL-18
binding protein (IL-18BP). Isolated as cytokine-binding
molecules, this 38-kDa soluble protein displays some
sequence homology with IL-18Ra [30-32]. IL-18BP
binds selectively and with high affinity to mature IL-18,
but not to pro-IL-18, preventing its interaction with IL-
18Ra. Four human (18BPa-d) and two murine (IL-
18BPc and d) IL-18BP isoforms have been described
[33]. Of these human IL-18BPb and d lack the structural
requirement to inhibit IL-18 action and their role
remains to be determined [5].
A different member of the IL-1 family, IL-1F7, is also
a negative regulator of IL-18 action. IL-1F7 is able to
bind IL-18BP and the IL-18BP/IL-1F7 complex can
interact with the IL-18Rb chain preventing the forma-
tion of the funtional IL-18R complex [34]. Several
human IL-1F7 splice variants (IL-1F7a-e) have been
described [35-39] whereas no murine homologue of IL-
1F7 has yet been found. Of these, IL-1F7b (also known
as IL-1H, IL-1H4 and IL-1RP1) matured by caspase-1 is
capable of binding IL-18Ra [37,40]. Yet, the IL-1F7/IL-
18Ra complex failed to recruit IL-8Rb and no direct
agonistic nor antagonistic activity of IL-1F7b for IL-18R
was described [37,40].
IL-18 signaling
Canonical IL-18 action occurs via recruitment of the
adaptor myeloid differentiation factor (MyD88). This
event allows activation of the IL-1R-associated kinase
(IRAK)/tumor necrosis factor receptor-associated fac-
tor 6 (TRAF6) pathway leading to nuclear transloca-
tion of the nuclear factor kappa beta (NF-B) and
subsequent modulation of gene transcription
[4,5,41,42] (Fig 1).
IL-18 has also been reported to signal via the activa-
tion of the transcription factor tyk-2 [43], STAT3 [44]
Table 1 Representative neurophisiological and
neurophatological conditions involving IL-18
Condition Species Citation
Behavior
Sleep Rat/Rabbit [72]
Fever Mouse [73,162]
Feeding Mouse [10,11]
Learning and memory Mouse [77]
Rat [48,74,75]
Human [108,111,163]
Stress and HPA axis
Rat [56,57,81]
Rat/Mouse [62]
Holstein cattle [80]
Pig [54,55]
Human [136]
Neuroinflammation
Brain injury
Hypoxia-ischemia Mouse [67,84,164-167]
Rat [67,168]
Thromboembolic stroke Mouse [83]
Spinal cord injury Rat [87]
Focal brain ischemia Rat [86]
Stroke Mouse [59,85]
Human [169]
Nerve injury Rat [47]
Viral infection Chicken [170]
Human [59,171]
Autoimmune neurodegenerative disease
Multiple Sclerosis Human [95-99,101]
EAE Mouse [91,93,100]
Rat [89,90,92,94]
Neurodegenerative disease
Alzheimer’s disease Human [50,106-109,111-114]
Parkinson’s disease Mouse [117]
Neuropsychiatric disorders
Depression Rat [133]
Human [136,137,139]
Schizophrenia Human [134,135]
Other central actions
Excitotoxic damage
Ataxia Mouse [53]
Neurodegeneration Mouse [150]
Glioma Rat [156,157]
Mouse [152-155]
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vated protein kinases (MAPK) (i.e., extracellular signal-
regulated kinase, ERK1/2 and p38), and phosphatidyli-
nositol-3 kinase (Pi3K) in IL-18 signalling has been sug-
gested [4,44-46].
While these data on peripheral cells were consolidated
over a decade of work with the immune system, knowl-
edge of the IL-18-dependent signaling in the CNS is
only beginning to emerge. Activation of the IL-18R
increased NF-B phosphorylation and induced hypertro-
phy in astrocytes [47]. In the rat dentate gyrus, the func-
tional effects of IL-18 were significantly attenuated by
prior application of c-jun-n-terminal kinase (JNK) path-
way, cyclooxygenase-2 (COX-2) and inducible nitric
oxide synthase (iNOS) inhibitors, and a role for p38
MAPK was also suggested [48,49]. Moreover, human
neuron-like differentiated SH-SY5Y neuroblastomas
exhibited an IL-18-dependent increase in the levels of
several kinases including p35, Cdk5, GSK-3beta, and
Ser15-phosphorylated p53 [50].
IL-18 system in the CNS
IL-18 transcript was demonstrated by RT-PCR in a vari-
ety of brain regions including the hippocampus, the
hypothalamus and the cerebral cortex [51,52]. In in vivo
Figure 1 The IL-18 system. Active IL-18 is produced and secreted after proteolitic cleavage of the biological inactive precursor Pro-IL-18 by
caspase-1. IL-18 action can be regulated by the IL-18 binding protein (IL18-BP) that binds IL-18 with high affinity and inhibits its function. Free
IL-18 binds to a specific heterodimeric cell surface receptor, a member of the IL-1 receptor/Toll like receptor superfamily comprised of two
subunits, IL-18Ra (here referred to as IL-18RaI) and IL-18Rb, both with three extracellular Ig-like domains and one intracellular portion containing
the Toll/IL-1R domain (TIR). Interaction of IL-18 with the IL-18Ra stabilizes its interaction with IL-18Rb and with the adaptor protein MyD88 via
the TIR domain. This initiates signal transduction by recruitment of the IL-1 receptor activating kinase (IRAK). IRAK autophosphorylates and
dissociates from the receptor complex subsequently interacting with the TNFR-associated factor-6 (TRAF6) eventually leading to nuclear
translocation of the nuclear factor B (NF-B). Engagement of the IL-18R complex can also activate STAT3 and the mitogen-activated protein
kinase (MAPK) p38, JNK and ERK. One truncated variant of IL-18Ra (IL-18RaII) lacking the intracellular TIR domain, and one soluble isoform of the
IL-18Rb (sIL-18Rb) were demonstrated in vivo in the mouse brain and in the rat and human brain, respectively. These isoforms originating from
differential splicing are proposed to be decoy receptors and possible negative regulators of IL-18 fuction. IL-1F7 is another proposed regulator of
IL-18 action (see text for details).
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gland, ependymal cells, the neurons of the medial habe-
nula (where its synthesis was elevated by stress), in Pur-
kinje cells, and in astrocytes in the cerebellum [53-57].
In addition, it was demonstrated in vitro that microglia
and astrocytes can produce IL-18 [58-61] and its level
can be up-regulated following LPS stimulation [62] or
treatment with INF-g [63].
In the CNS, Northern blot analysis failed to detect
t h ep r e s e n c eo fI L - R a [64] and IL-Rb [65] soon after
their cloning. The first evidence that IL-18R compo-
nents are expressed in brain tissue was obtained by
Wheeler and colleagues [52] which reported the con-
stitutive expression of IL-18Ra, IL-18Rb in the rat
hypothalamus by RT-PCR. Subsequently, the mRNA
expression of IL-18Ra, IL-18Rb and the soluble form
of the IL-18Rb were detected in the hypothalamus,
hippocampus, striatum and cortex and in cultured
astrocytes, microglia and neurons [28]. More recently
in vivo analysis showed that IL-18Ra mRNA and pro-
tein are constitutively expresseed in neurons through-
out the brain [26,53,60,66]. Similar neuronal
localization and distribution was found for IL-18Rb
(Alboni et al., unpublished data). At the same time it
was demonstrated that the truncated decoy form of
the IL-18Ra was expressed in neuronal cells with a
pattern similar to that of its active counterpart [26].
Overall, IL-18R subunits had broad distribution across
the brain with the highest level in the hypothalamus,
hippocampus and amygdala. Finally, both IL-18 and
IL-18R subunits are inducible and their CNS levels can
be regulated. For instance, in the mouse hippocampus
the levels of IL-18 and IL-18Ra increased after kainic
acid (KA)-induced excitotoxicity, [60] whereas
hypoxic-ischemic brain inju r ym a r k e d l yi n c r e a s e dI L -
18 expression in mouse microglia [67]. In addition
nerve injury induced IL-18 upregulation in rat spinal
cord microglia possibly via p38 activation [47].
IL-18BP has been investigated and demonstrated in
rodent brains, mixed glia and microglia by only one
group using RT-PCR. Its distribution and action in the
CNS remain to be investigated [52,68].
Information on central IL-1F7 is also limited to one
study that demonstrated its presence in the human
brain [37]. Investigating IL-1F7 in the CNS is also ham-
pered by the fact that a mouse homologue has not been
identified.
Behavior
The similarities between the IL-1 and the IL-18 systems
suggested the possibility that like IL-1b,I L - 1 8m a yb e
one mediator of the behavior symptoms of sickness.
These include fever, lethargy, hypophagia and cognitive
alterations [69-71].
It was demonstrated that central intracerebroventricular
(i.c.v.) injection of IL-18 in rabbits and rats increased non-
rapid eye movement sleep as well as brain temperature
[72]. The lethargic effects of IL-18 were also observed fol-
lowing intraperitoneal injection of IL-18, whereas, unlike
IL-1b, peripheral administration did not induce fever
[72,73]. Instead, pre-treatment with IL-18 reduced the
pyrogenic effects of IL-1 suggesting the possibility of an
antagonizing effect of these cytokines on fever [73].
Work on IL-18 null, and on IL-18BP overexpressing
mice indicated that IL-18 is anorexigenic and can mod-
ulate feeding, but also energy homeostasis, influencing
obesity and insulin resistance [10,11]. The mechanisms
through which IL-18 exerts these effects are largely
unknown but central action was proposed following the
observation that i.c.v. injections of exogenous IL-18
induces sleep [72] and anorexia [11]. The recent demon-
stration that IL-18 functional and regulatory subunits of
the IL-18R are expressed in several brain regions includ-
ing the hippocampus, the hypothalamus and the cortex
provided a molecular and cellular basis for the central
action of IL-18 in modulating these functions [26].
Evidence for the role of IL-18 as modulator of neuro-
nal functions includes studies on the hippocampal sys-
tem, a structure that plays a major role in memory and
in cognition. For instance, IL-18 reduces long term
potentiation (LTP) in the rat dentate gyrus, possibly
through the involvement of metabotropic glutamate
receptors [48,49,74,75]. In particular, IL-18 had no effect
on baseline synaptic transmission or paired pulse
depression, but significantly depressed the amplitude of
NMDA receptor-mediated field excitatory post synaptic
potentials [75] providing evidence of a direct neuromo-
dulatory role for IL-18 in synaptic plasticity. It is possi-
ble that IL-18 may act directly on the neurons of the
dentate gyrus, moreover, its action may be regulated by
the relative level of IL-18Ra type I and type II, both
highly expressed in these cells [26]. Work on CA1 pyra-
midal neurons of mouse hippocampal slices demon-
strated that IL-18 stimulated synaptically released
glutamate and enhanced postsynaptic AMPA receptor
responses, thereby facilitating basal hippocampal synap-
tic transmission without affecting LTP [76].
Recently an ex vivo study found that LPS-induced IL-
18 elevation in the brain was unable to affect LTP in
the CA1 hippocampal subregion [77]. However, when
comparing wild-type and IL-18 KO mice, the same
study demonstrated that IL-18 regulates fear memory
and spatial learning. In particular, assessment of spatial
learning and memory with the water maze test showed
that compared to wild-type mice IL-18 KO mice exhibit
prolonged acquisition latency and that this phenotype
was rescued by i.c.v. injection of IL-18.
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IL-18 occupies a peculiar role in stress response both
centrally and peripherally. This subject was recently
extensively reviewed and we briefly refer to it here only
for those aspects relevant to understanding of the cen-
tral actions of this cytokine [78].
In response to restraint stress, IL-18 null mice showed
a markedly reduced morphological microglial activation
in the thalamus, hypothalamus, hippocampus, substantia
nigra and central gray area [62]. In addition, IL-18
expression was elevated by restraint stress in the neu-
rons of the medial habenula [56]. Since the habenula is
a potential site for the interaction of neuro-endocrine
and immune functions, the possibility exists that IL-18
might mediate the communication between the CNS
and the periphery. Indeed, there is a general agreement
that IL-18 may regulate hypothalamic-pituitary axis
activity, possibly mediating the stress response of the
adrenal gland [20,78,79]. In this respect, stress has been
shown to induce transient IL-18 mRNA elevation in rat
pituitary cells where increase of the IL-18 mRNA level
was observed also after adrenalectomy [57].
IL-18 is also produced in the neurohypophysis [20] as
well as in the adenohypophysis where in situ hybridiza-
tion combined with immunohistochemistry demon-
strated its expression in corticotrope cells [57]. In
addition, bovine somatotropes have been shown to pro-
duce IL-18 and IL-18Ra was co-localized with IL-18, or
growth hormone, suggesting the possibility that IL-18
acts on somatotropes through the autocrine pathway
[80]. However, IL-18 seems to also act at the hypothala-
mic level. Indeed, the application of IL-18 in rat
hypothalamic explants decreases basal and KCl-stimu-
lated corticotropin-releasing hormones (CRH), as well as
CRH gene expression [81]. In particular, the cytokine
did not modify basal PGE2 production but abolished
production stimulated by IL-1b demonstrating that IL-
18 possesses a profile of in vitro neuroendocrine activ-
ities opposed to, and even antagonizing, those of IL-1b.
Recently, IL-18 was localized in the marginal cell layer
o ft h eb o v i n ea n dp o r c i n eR a t h k e ’sp o u c h ,t h a ti s
assumed to embody a stem/progenitor cell compartment
of the postnatal pituitary gland [54,55]. Interestingly, sti-
mulation of a cloned anterior pituitary-derived cell line
(from the bovine anterior pituitary gland) with IL-18
increased expression of mRNAs of a different cytokine
suggesting the possibility that IL-18 may modulate not
only the immuno-endocrine function of the pituitary
cells but also their development [55].
Microglia and neuroinflammation
Functional maturation and activation of IL-18 can occur
in the brain under inflammatory conditions. Indeed, as
extensively reviewed by Felderhoff-Mueser and collea-
gues [82], experimental and clinical studies suggest that
binding of IL-18 occurs in several neuroinflammatory
associated pathological conditions including microbial
infections, focal cerebral ischemia, Wallerian degenera-
tion and hypoxic-ischemic, hyperoxic and traumatic
brain injuries (e.g., stroke). Further evidence comes from
recent papers reporting an activation of IL-18 in the
brain of mice that underwent thromboembolic stroke
[83] or an increase of IL-18 levels after hypoxia-ischemia
in the juvenile hippocampus of mice [84].
During CNS inflammation, the IL-18 system may have
an important role in the activation and response of
microglia and possibly infiltrating cells. As mentioned
above, microglia cells can synthesize and respond to IL-
18 [20,59-61]. IL-18 KO mice had impaired microglia
activation with reduced expression of Ca
2+-binding pro-
tein regulating phagocytic functions that resulted in
reduced clearance of neurovirulent influenza A virus
[85]. In the absence of infection IL-18 deficient mice
also showed diminished stress-induced morphological
microglial hypertrophy [62].
Interestingly, IL-1b is upregulated within 4 h of focal
ischemia in rat brain, but IL-18 is upregulated much
later, at time points associated with infiltration of per-
ipheral immune cells, thus suggesting different roles for
these interleukins in the regulation of glial functions
[86]. In this respect, it was shown that mice infected
with Japanese Encephalitis produce IL-18 and IL-1b
from microglia and astroglia [59]. Both interleukins are
capable of inducing pro-inflammatory cytokines and
chemokines from human microglia and astroglia,
although IL-18 seems to be more potent than IL-1b.
In the spinal cord, IL-18 seems to play a role in the
innate inflammatory response. Indeed, moderate cervical
contusive spinal cord injury induced processing of IL-18
in neurons of the rat spinal cord [87]. In addition, nerve
injury induced a striking increase in IL-18 and IL-18R
expression in the dorsal horn, and IL-18 and IL-18R
were upregulated in hyperactive microglia and astro-
cytes, respectively [47,88]. Intrathecal injection of IL-18
induced behavioral, morphological, and biochemical
changes similar to those observed after nerve injury
[47], suggesting that IL-18-mediated microglia/astrocyte
interactions in the spinal cord have a substantial role in
the generation of tactile allodynia.
Autoimmune neurodegenerative disease
A pivotal role for IL-18, in the pathogenesis of autoim-
mune neurodegenerative disease has been proposed.
High levels of IL-18 mRNA were found in the brain and
the spinal cord of rats with experimental autoimmune
encephalomyelitis (EAE), an animal model of multiple
sclerosis (MS) [89,90]. Elevated IL-18 transcript was
found at the onset and throughout the course of the dis-
ease. A different study showed that IL-18 increases
severity of EAE [91]. Moreover, it has been
Alboni et al. Journal of Neuroinflammation 2010, 7:9
http://www.jneuroinflammation.com/content/7/1/9
Page 5 of 12demonstrated that anti-IL-18 antibodies or targeted
overexpression of IL-18BP in the CNS had preventive
effects on the induction of EAE[90,92]. These observa-
t i o n ss u g g e s t e dar o l ef o rI L - 1 8i nM S ,I L - 1 8K Om i c e
were susceptible to EAE, whereas IL-18Ra KO mice or
IL-18 KO mice treated with anti-IL-18Ra antibodies
were not [93]. Thus, alternative IL-18Ra ligands with
encephalitogenic properties may exist [93]. In EAE-sus-
ceptible Dark Agouti rats, the basal and post-immuniza-
tion (day 5, 7 and 12) levels of IL-18Ra in lymph node
cells were significantly higher than in the EAE-resistant
Piebald Virol Glaxo rats [94].
In human, serum and cerebrospinal fluid levels of IL-
18 are elevated in patients with MS [95-98] and IL-18
positive cells have been detected in demyelinating brain
lesions from MS patients [99].
The pathological role of IL-18 in EAE is also sup-
ported by the up-regulation of caspase-1 (required to
convert IL-18 precursor protein into its biologically
active mature form) mRNA in the spinal cord of rats
with EAE [89], and decreased disease severity in cas-
pase-1 KO mice [100]. Finally, peripheral blood mono-
nuclear cells from patients with MS have elevated
caspase-1 mRNA levels [95,101].
In addition to a role in MS there is also evidence to
support a function for IL-18 in the onset and progres-
sion of autoimmune CNS disease. For instance, infection
of microglia lines with Theiler’s murine encephalomyeli-
tis virus (which causes the development of a chronic-
progressive autoimmune demyelinating disease) signifi-
cantly upregulates the expression of cytokines involved
in innate immunity, including IL-18 [102].
Neurodegenerative disorders
Alzheimer’s Disease (AD) is the most common type of
human dementia. It is characterized clinically by a gra-
dual but progressive decline in memory and pathologi-
cally by neuritic plaques, neuro-fibrillary tangles, and
t h el o s so fs y n a p s e sa n dn e u r o n s[ 1 0 3 ] .I n f l a m m a t o r y
processes were proposed to contribute to neurodegen-
eration in AD and extensive studies indicated that IL-1
is a pivotal cytokine in mediating direct neuronal loss
and sustaining microglia activation leading to further
cellular damage in AD [104]. Microglia-derived inflam-
matory cytokines can initiate nerve cell degeneration
and enhance the plaque production typically found in
AD [105]. Increasing evidence indicates that IL-18 may
h a v ear o l ei nt h i ss c e n a r i o .
For instance, the levels of IL-18 transcript and pro-
tein were increased in the frontal lobe of AD patients
compared to healthy age-matched controls. In these
brains IL-18 was found in microglia, astrocytes and in
neurons that co-localize with amyloid-b-plaques and
with tau [106], suggesting that amyloid-b may induce
the synthesis of IL-18, and IL-18 kinases involved in
tau phosphorylation as a part of the amyloid-associated
inflammatory reaction. Additionally, IL-18 can enhance
protein levels of Cdk5/p35 and GSK-3b kinases, tau
phosphorylation and cell cycle activators in neuron-
like differentiated human SH-SY5Y neuroblastoma
cells [50]. Thus, on a pathway leading to AD, IL-18
may have an impact on the hyperphosphorylation of
tau but also on cell cycle related mechanisms. In the
plasma, the levels of IL-18 were significantly elevated
in patients with AD, vascular dementia, and mild cog-
nitive impairment compared to the control group
[107,108]. Interestingly, IL-18 levels were higher in
AD-mild patients, were slightly lower in AD-moderate
patients, whereas no significant difference was
observed between AD-severe patients and non-demen-
ted age-matched subjects [109], suggesting a gradual
decline of immune responsiveness in AD. Although
other studies showed no differences in circulating IL-
18 levels measured between AD patients (both mild
cognitive impairment and severe AD patients) and
controls [106,110,111], a significant increased produc-
tion of IL-18 was obtained from stimulated blood
mononuclear cells or macrophages of peripheral blood
of AD patients [111,112]. Furthermore, a significant
correlation between IL-18 peripheral production and
cognitive decline was observed in AD patients. Overall,
these data indicate that IL-18-related inflammatory
pathways, are exacerbated in the peripheral blood of
AD patients, and that this cytokine may indeed partici-
pate in pathogenic processes leading to dementia.
Genetic association studies reported that two func-
tional polymorphisms (137G/C and -607C/A) in IL-18
promoter may increase the risk of developing sporadic
late onset AD in the Han Chinese population [113]. An
association between 137G/C and -607C/A polymorph-
isms and the susceptibility/clinical outcome of AD was
also suggested in an Italian population [114], although
these correlations remain controversial. Indeed, in
another Italian population a lack of association between
IL-18 gene promoter polymorphisms and onset of AD
was reported, indicating that the association of IL-18
promoter polymorphisms with AD is not so strong, AD
being a multifactorial disease [115]. Importantly, IL-18
promoter remains poorly characterized.
Finally, it has been hypothesized that increased pro-
duction of IL-18 in the brain may lead to motor and
cognitive dysfunctions, leading to the development of
HIV-associated dementia. Thus, IL-18 concentrations in
HIV-infected persons are likely to play an important
role in the development and progression of the infection
toward AIDS and associated clinical conditions [116].
In Parkinsonism, there is evidence of chronic inflam-
mation in the substantia nigra and striatum. Activated
microglia, producing proinflammatory cytokines,
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may contribute to dopaminergic neuron loss. In an
experimental model of Parkinson’s disease that utilized
injection of the dopaminergic specific neurotoxin MPTP
the number of activated microglial cells in the substantia
nigra pars compacta of IL-18 KO mice was reduced
compared to wild-type [117], indicating the possibility
that IL-18 may participate in microglial activation and
dopaminergic neurodegeneration.
Neuropsychiatric disorders
Several groups found that depressed and schizophrenic
patients have high circulating levels of pro-inflammatory
cytokines [118-123]. Others reported that psychotic epi-
sodes often occur in conditions characterized by ele-
vated levels of pro-inflammatory cytokines, for instance
during inflammation or in patients suffering from
immune diseases [124-127].
Other studies suggested that the correlation between
inflammatory markers and psychiatric disorders may be
more that merely associative, with inflammation actually
contributing to mental disorders. Improvement in psy-
chiatric symptoms has been recently reported in patients
treated with anti-inflammatory drugs for other indica-
tions [128] and functional allelic variants of genes codi-
fying for pro-inflammatory cytokines were associated
with reduced responsiveness to antidepressant therapy
[129,130]. It was also recently demonstrated that IL-6
plays a pivotal role in the pharmacological ketamine
model of schizophrenia by modulating the NADPH-oxi-
dase increase of superoxide affecting parvalbumin inter-
neurons [131]. An interesting line of research is
exploring the possibility that these actions may be devel-
opmental, with cytokines influencing early-life program-
ming of brain functions [132].
At present evidence linking IL-18 and psychiatric dis-
orders are primarily associative. IL-18 mRNA expression
is elevated in subordinate rat models with depression
with respect to dominant rats [133]. A significant eleva-
tion of circulating plasma levels of IL-18 has been
reported in subjects affected by schizophrenia and were
normalized by pharmacological treatment with risperi-
done, a dopamine antagonist with antipsychotic activity
[134,135]. Normalization was demonstrated also within
6 month of treatment with the antipsychotic clozepine
[134] although the possibility that these effects could be
due to clozepine’s effects on leukocyte numbers cannot
be excluded. The serum levels of IL-18 were also signifi-
cantly higher in moderate-severe depression patients,
further suggesting that the pathophysiology of depres-
sion is associated with an inflammatory response invol-
ving IL-18 [136,137]. Coincidentally, IL-18 is also
elevated after stroke, a condition followed by emotional
disorders [138-140].
The significance of these correlations with respect to
the role of the IL-18 system to neurophsychiatric disease
pathophysiology or manifestation remains to be deter-
mined. Caution should be taken particularly since per-
ipheral IL-18 can be subject to neurogenic stimulation
or stress [20,78,141-143]. It is thus difficult to determine
whether IL-18 elevation contributes to these pathologies
or whether it is a consequence of the disorders. Indeed,
Kokai and colleagues suggest that IL-18 can be consid-
ered a psychologic stress-associated marker since they
demonstrated that exposure to stressful events (i.e.,
panic attack in human, restraint stress in mice), the
most important precipitating factor in depression,
induces a prompt increase in the level of circulating IL-
18 [136].
Regardless, elevated IL-18 levels have the potential to
contribute to several of the symptoms associated with
neuropsychiatric disorders. For instance, like other
pro-inflammatory cytokines, IL-18 may participate in
the control of the activity of the HPA axis reported to
be dysregulated in depression [78,144-146]. IL-18 may
antagonize glucocorticoid signalling via activation of
NF-B and p38 MAPK possibly disrupting glucocorti-
coid-dependent negative feedback on the HPA axis
[147-149]. Finally, IL-18 can affect other hallmarks of
depression impairing learning and memory by acting
as an attenuator of long-term potentiation, and indu-
cing lethargy and loss of appetite [11,72,74].
Other central actions of IL-18
Three groups investigated the action of IL-18 in
rodents following administration of KA, an agonist of
the kainate receptors inducing seizure, cerebellar ataxia
and exitotoxic mediated neuronal loss [53,60,150]. In
mouse hippocampus KA elevated IL-18 and IL-18R
expression on microglial cells progressively 3 days after
treatment [60]. The authors hypothesized that similar
to what was observed peripherally in studies of the
immune system, IL-18 may contribute to cellular
damage. This hypothesis was partially supported by
another group showing that the KA-induced hippo-
campal neurodegeneration was shown to be more
severe in IL-18 KO mice compared to wild-type litter-
mates [150]. Yet, in recombinant mice with the same
pre-treatment, IL-18 aggravated both the clinical and
pathological signs of neurodegeneration in a dose-
dependent manner.
In the cerebellum, where KA was demonstrate to
induce ataxia partially via elevation of IL-1b,e x o g e n -
ous IL-18 was protective and played a positive role in
the recovery from kainate-induced ataxia [53]. Consis-
tently, IL-18 KO and IL-18Ra KO mice show delay in
recovery from kainate-induced ataxia. The antagoniz-
ing effects of IL-18 and IL-1b also observed in the per-
ipheral effects of IL-1b on fever, [73] are intriguing
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ties including their signalling. Preliminary observations
suggest that these effects may be explained by IL-1b
and IL-18 targeting different cells or activating distinct
signalling [53].
Some groups have investigated the possibility that
IL-18 could be used against glioma, a common and
highly aggressive type of brain tumor with poor long-
term prognosis [151]. In this respect, IL-18 was inves-
tigated alone or in synergism with IL-12 or Fas, for its
ability to induce INFg and NO inducing a cytotoxic
response against glioma cells [152]. Systemic or intra-
cerebral administration of IL-18 inhibited the growth
of inoculated glioma cells and prolonged the survival
of mice with subcutaneous or brain tumors, respec-
tively [153]. Antitumor activity against glioma was also
found in mice treated with IL-18 and IL-12 via Semliki
Forest virus [154,155] or with a combination of IL-18
and Fas [156]. Finally, encouraging data were also
reported by overexpressing IL-18 in mesenchymal cells
of rats [157].
Conclusions
Investigation on the presence of IL-18 in the CNS began
soon after its discovery as a co-stimulator of INF-g pro-
duction in the immune system [1,20,158,159]. Initially
IL-18 was investigated for its similarities with IL-1b as a
possible mediator of sickness behavior and of local
inflammatory reactions associated with neuronal
damage. These actions were both demonstrated and IL-
18 was shown to promote loss of appetite, sleep and
inhibition of LTP, as well as to be produced by and
active in microglial cells, and to possibly contribute to
neurodegenerative diseases.
Yet, two observations suggest that IL-18 has a central
role and function that may be unique and distinct from
those of IL-1b or other cytokines. The first being the
recognition that Il-18 and Il-1b, when their combined
action was tested, may have antagonizing effects such as
those occurring in fever and in kainate-induced cerebel-
lar ataxia. The second was the finding that IL-18R is
constitutively and broadly expressed in neuronal cells
throughout the rodent brain. This finding opened the
possibility of a direct action of IL-18 on neuronal func-
tions particularly in all of the CNS disorders showed to
be correlated to elevated cytokine levels.
Thus, the investigation of the central action of IL-18
may be considered in its infancy and the significance of
the neuronal IL-18R complex and of its isoforms
remains to be determined. Among the intriguing pecu-
liarities of the central role of IL-18 is that despite the
constitutive expression of the receptor, the regulation of
IL-18 action appears to be regulated by the existence of
truncated isoforms and by the fact that under normal
physiological conditions IL-18 is not easily found in the
CNS. Interestingly, the genes encoding for IL-18 and its
receptors are subject to differential promoter usage and
their transcription to differential splicing indicating that
these molecules have the potential of being produced in
a tissue/cell specific way in response to different stimuli
[26,78]. It will be important to determine which physio-
logical or pathological conditions modulate these
molecules.
Also unexplored is the investigation of the possible
role of IL-18 in CNS development suggested by work
on microglial cultures from newborn mice and brain
homogenates where IL-18 was preferentially expressed
during early postnatal stages and subsequently downre-
gulated, being virtually absent in the brains of adult
mice [61]. Additionally, the activated microglia-derived
cytokines, including IL-18, may either inhibit the neu-
ronal differentiation or induce neuronal cell death in
the rat neural progenitor cell culture, which are cells
capable of giving rise to various neuronal and glial cell
populations in the developing and adult CNS [160].
Finally, in adult rodents IL-18 is produced in ependy-
mal cells [56] considered a primary source of neural
stem cells in response to injury [161]. The possible
role of IL-18 in their differentiation has also not been
investigated.
Work on existing IL-18 and IL-18R null mice as well
as the development of new experimental models includ-
ing CNS specific null or overexpressor mice and the
identification of suitable in vitro systems will determine
the specificity of the central effects of IL-18 in health
and disease.
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